Facteur de maturation gliale : Questions médicales fréquentes
Nom anglais: Glia Maturation Factor
Descriptor UI:D020904
Tree Number:D23.529.850.325
Termes MeSH sélectionnés :
Case-Control Studies
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Facteur de maturation gliale : Questions médicales les plus fréquentes",
"headline": "Facteur de maturation gliale : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Facteur de maturation gliale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-02",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Facteur de maturation gliale"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteurs de croissance nerveuse",
"url": "https://questionsmedicales.fr/mesh/D009414",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de croissance nerveuse",
"code": {
"@type": "MedicalCode",
"code": "D009414",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.850"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Facteur de maturation gliale",
"alternateName": "Glia Maturation Factor",
"code": {
"@type": "MedicalCode",
"code": "D020904",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Duraisamy Kempuraj",
"url": "https://questionsmedicales.fr/author/Duraisamy%20Kempuraj",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA."
}
},
{
"@type": "Person",
"name": "Ramasamy Thangavel",
"url": "https://questionsmedicales.fr/author/Ramasamy%20Thangavel",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA."
}
},
{
"@type": "Person",
"name": "Mohammad Ejaz Ahmed",
"url": "https://questionsmedicales.fr/author/Mohammad%20Ejaz%20Ahmed",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA."
}
},
{
"@type": "Person",
"name": "Govindhasamy Pushpavathi Selvakumar",
"url": "https://questionsmedicales.fr/author/Govindhasamy%20Pushpavathi%20Selvakumar",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA."
}
},
{
"@type": "Person",
"name": "Sudhanshu P Raikwar",
"url": "https://questionsmedicales.fr/author/Sudhanshu%20P%20Raikwar",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A case-control study on immunologic markers of patients with vitiligo.",
"datePublished": "2022-10-14",
"url": "https://questionsmedicales.fr/article/36244264",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biopha.2022.113785"
}
},
{
"@type": "ScholarlyArticle",
"name": "Case-Control Study of Long COVID, Sapporo, Japan.",
"datePublished": "2023-04-12",
"url": "https://questionsmedicales.fr/article/37044126",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3201/eid2905.221349"
}
},
{
"@type": "ScholarlyArticle",
"name": "Endothelium-biomarkers for postthrombotic syndrome: a case-control study.",
"datePublished": "2023-03-29",
"url": "https://questionsmedicales.fr/article/37016998",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MBC.0000000000001192"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk Factors for Postoperative Pneumonia: A Case-Control Study.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35875004",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2022.913897"
}
},
{
"@type": "ScholarlyArticle",
"name": "Significance of temperature in antimuscarinic toxicity: a case-control study.",
"datePublished": "2022-06-23",
"url": "https://questionsmedicales.fr/article/35735006",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/15563650.2022.2088378"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Facteurs de croissance nerveuse",
"item": "https://questionsmedicales.fr/mesh/D009414"
},
{
"@type": "ListItem",
"position": 5,
"name": "Facteur de maturation gliale",
"item": "https://questionsmedicales.fr/mesh/D020904"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Facteur de maturation gliale - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Facteur de maturation gliale",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Facteur de maturation gliale",
"description": "Comment diagnostiquer une anomalie des facteurs de maturation gliale ?\nQuels tests sont utilisés pour évaluer les facteurs gliaux ?\nLes facteurs de maturation gliale sont-ils mesurables ?\nQuels signes cliniques indiquent un problème glial ?\nLes tests génétiques sont-ils utiles pour ces facteurs ?",
"url": "https://questionsmedicales.fr/mesh/D020904?mesh_terms=Case-Control+Studies&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Facteur de maturation gliale",
"description": "Quels symptômes sont liés à une dysfonction gliale ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes physiques associés ?\nLes symptômes sont-ils réversibles ?\nComment les symptômes affectent-ils la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D020904?mesh_terms=Case-Control+Studies&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Facteur de maturation gliale",
"description": "Peut-on prévenir les troubles liés aux facteurs gliaux ?\nY a-t-il des facteurs environnementaux à éviter ?\nL'éducation joue-t-elle un rôle dans la prévention ?\nLes vaccinations peuvent-elles prévenir des troubles gliaux ?\nLe soutien psychologique est-il préventif ?",
"url": "https://questionsmedicales.fr/mesh/D020904?mesh_terms=Case-Control+Studies&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Facteur de maturation gliale",
"description": "Quels traitements sont disponibles pour les troubles gliaux ?\nLes thérapies comportementales sont-elles efficaces ?\nY a-t-il des traitements expérimentaux ?\nLes traitements sont-ils personnalisés ?\nQuel rôle joue la rééducation dans le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D020904?mesh_terms=Case-Control+Studies&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Facteur de maturation gliale",
"description": "Quelles complications peuvent survenir avec des troubles gliaux ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles le quotidien ?\nY a-t-il des risques de complications à long terme ?\nLes complications nécessitent-elles une surveillance continue ?",
"url": "https://questionsmedicales.fr/mesh/D020904?mesh_terms=Case-Control+Studies&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Facteur de maturation gliale",
"description": "Quels sont les principaux facteurs de risque pour les troubles gliaux ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il les risques ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nY a-t-il des facteurs génétiques impliqués ?",
"url": "https://questionsmedicales.fr/mesh/D020904?mesh_terms=Case-Control+Studies&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des facteurs de maturation gliale ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques et des analyses histologiques des tissus nerveux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les facteurs gliaux ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie cérébrale et des biopsies peuvent être utilisés pour évaluer les facteurs gliaux."
}
},
{
"@type": "Question",
"name": "Les facteurs de maturation gliale sont-ils mesurables ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dosages spécifiques dans le liquide céphalorachidien peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un problème glial ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques, des déficits cognitifs ou des symptômes psychiatriques peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour ces facteurs ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations associées aux anomalies des facteurs gliaux."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysfonction gliale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles de la mémoire, des convulsions et des changements de comportement."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'âge et du stade de développement neurologique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes physiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes physiques comme des douleurs ou des faiblesses musculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la cause sous-jacente; certains symptômes peuvent être réversibles avec un traitement."
}
},
{
"@type": "Question",
"name": "Comment les symptômes affectent-ils la qualité de vie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent gravement affecter la qualité de vie, entraînant des limitations fonctionnelles et sociales."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux facteurs gliaux ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures préventives, comme une bonne nutrition et l'exercice, peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines et à des infections peut augmenter le risque de troubles gliaux."
}
},
{
"@type": "Question",
"name": "L'éducation joue-t-elle un rôle dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les signes précoces peut aider à une intervention rapide et efficace."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles prévenir des troubles gliaux ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui affectent le système nerveux."
}
},
{
"@type": "Question",
"name": "Le soutien psychologique est-il préventif ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le soutien psychologique peut réduire le stress et améliorer la résilience face aux troubles."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles gliaux ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments, la thérapie physique et des interventions chirurgicales si nécessaire."
}
},
{
"@type": "Question",
"name": "Les thérapies comportementales sont-elles efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent aider à gérer les symptômes psychiatriques associés aux troubles gliaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements expérimentaux, comme la thérapie génique, sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la rééducation dans le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La rééducation est essentielle pour améliorer la fonction et la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des troubles gliaux ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles cognitifs, des crises épileptiques et des troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles le quotidien ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des limitations dans les activités quotidiennes et la vie sociale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications à long terme peuvent survenir, affectant la santé mentale et physique."
}
},
{
"@type": "Question",
"name": "Les complications nécessitent-elles une surveillance continue ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance régulière est essentielle pour gérer les complications et ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les troubles gliaux ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux, des infections et des traumatismes crâniens."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles gliaux sont plus fréquents chez les personnes âgées ou les jeunes enfants."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les risques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies auto-immunes peuvent affecter la fonction gliale et augmenter les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations génétiques peuvent prédisposer certains individus à des troubles gliaux."
}
}
]
}
]
}
Vitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5-2 % of the world's population. A combination of genetic, environmental and biochemical...
We conducted a cross-sectional survey among SARS-CoV-2-positive persons and negative controls in Sapporo, Japan, to clarify symptoms of long COVID. We collected responses from 8,018 participants, 3,69...
The postthrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT). Increase knowledge on the PTS pathophysiology and novel biomarkers are needed in order to predict PTS dev...
A case-control study was conducted. Inclusion criteria were symptomatic and confirmed DVT patients treated with anticoagulants for at least 3 months. Villalta score was performed at the time of inclus...
Thirty two patients and 61 controls were included. PTS patients showed higher levels of CEC (0.56/μl (0.34-1.5) vs. 0.20/μl (0.11-0.77); P = 0.04) and EPC (0.75/μl (0.38-1.52) vs. 0.09/μl (0.05-0.82);...
The formation and early resolution of DVT are characterized by inflammation and endothelial/platelet activation. We have identified possible novel biomarkers such as CEC, EPC and fractalkine for the d...
Postoperative pneumonia is a preventable complication associated with adverse outcomes, that greatly aggravates the medical expenses of patients. The goal of our study is to identify risk factors and ...
A matched 1:1 case-control study, including adult patients who underwent surgery between January 2020 and June 2020, was conducted in the Second Affiliated Hospital of Kunming Medical University in Ch...
Out of 17,190 surgical patients, 264 (1.54%) experienced postoperative pneumonia. Increased age, chronic obstructive pulmonary disease, emergency surgery, postoperative reduced albumin, prolonged vent...
Postoperative pneumonia is associated with severe clinical outcomes. We identified six independent risk factors that can aid in risk stratification and management of patients at risk of postoperative ...
www.chictr.org.cn, identifier: chiCTR2100045986....
Antimuscarinic toxicity can result in temperature dysregulation, but the clinical significance of this is unclear. The objective of this study was to compare peak temperatures between antimuscarinic p...
This was a case-control analysis at two large, urban, academic medical centers from January 1, 2016, through December 31, 2021. We compared peak temperature (...
Fifty-six patients met inclusion criteria of which 23 developed severe outcomes: 16 seizures, 9 cases with hypotension, 5 intubations, and 2 ventricular dysrhythmias. Tmax amongst all patients ranged ...
Maximum temperatures did not differ between patients with and without severe outcomes in the setting of antimuscarinic toxicity, and temperature was poorly predictive of outcomes. Our findings suggest...
Asbestos lung content is regarded as the most reliable tool for causal attribution of malignant mesothelioma (MM) to previous asbestos exposures. However, there is a lack of studies on asbestos burden...
Asbestos lung content has been assessed on formalin-fixed lung fragments using scanning electron microscopy coupled with energy dispersion spectroscopy (SEM-EDS) on individuals deceased from MM (cases...
Asbestos and asbestos bodies (ABs) were found, respectively, in 73.7% and 43.2% of cases and in 28 and 22% of controls; in MM cases the most represented asbestos types were crocidolite and amosite, wh...
The results suggest a correlation between asbestos burden in lungs and MM risk. The different concentration of chrysotile, as well as the different width of asbestos fibers in MM males and females mig...
Psoriasis (PsO) is a chronic inflammatory skin condition, often accompanied by psoriatic arthritis (PsA) and linked to various comorbidities and increased mortality rates. This study aimed to explore ...
Idiopathic intracranial hypertension (IIH) is a condition that mostly affects obese women of childbearing age but has been reported to be temporally related to new diagnoses of anemia. Despite these r...
Consecutive IIH patients were recruited from neuro-ophthalmology clinics and matched by age and sex to consecutive patients attending neuro-ophthalmology clinics with diagnoses other than IIH. Complet...
One hundred twenty-three IIH patients and 113 controls were included in the study. More IIH patients than controls had anemia (22.8%, 28/123 vs 10.6%, 12/113, P = 0.01) with an odds ratio of 2.48 (95%...
Idiopathic intracranial hypertension patients have a higher prevalence of anemia compared with non-IIH neuro-ophthalmology patients. The anemia was mostly mild and may be explained by other factors re...
Adverse drug reactions (ADRs) caused by opioid drugs show individual differences. Our objective was to explore the association between gene polymorphism and ADRs induced by opioid drugs....
Evidence-based medical data analysis was conducted for genes related to ADRs induced by opioid drugs to select target genes. Sixty patients with cancer pain who had ADRs after taking opioid drugs (mor...
Based on a database search and evidence-based medical data, we identified CYP2D6*10, CYP3A5*3, ABCB1, and OPRM1 as target genes for detection. The results of statistical analysis showed no significant...
Polymorphism of ABCB1 (062rs1045642) is related to ADRs caused by oxycodone, and the incidence of ADRs is higher with the allele T. Polymorphism of ABCB1 is expected to become a clinical predictor of ...
The effect of systemic hormone therapy (HT) on dementia risk is unclear. Our aim was to investigate the association between HT and dementia....
This register-based study consists of a nested case-control study and a co-twin control design, which controls for familial confounding, including shared genetics....
Through Danish national registries from 1995 to 2011, we identified: a) 2700 female singletons with incident dementia and 13,492 matched controls; b) 288 female twins with incident dementia and co-twi...
The odds ratio (OR) for the association between systemic HT and dementia was 1.05, 95% CI = [0.93-1.19] in singletons and 2.10, 95% CI = [0.99-4.46] in twins. A statistically significant association w...
Using Danish nationwide registries and controlling for education and for familial factors in a subsample, systemic HT was found to be associated with increased dementia risk if used before 2003, when ...